A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.
Journal article
van Tol S. et al, (2024), J Infect Dis, 230, 1083 - 1092
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model
Journal article
O’Donnell KL. et al, (2024), International Journal of Molecular Sciences, 25
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Journal article
Flaxman A. et al, (2024), PLoS Pathog, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Journal article
Bissett C. et al, (2024), NPJ Vaccines, 9
Translational Science at the Undergraduate Level: Awakening Talents to Overcome the Valley of Death – Viewpoint Showing a Success Case (Preprint)
Preprint
Ferreira Jr RS. et al, (2024)
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Journal article
Costa Clemens SA. et al, (2024), Lancet Microbe
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Journal article
Drury RE. et al, (2024), Nat Commun, 15
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Journal article
Waerlop G. et al, (2023), J Immunol Methods, 523
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Journal article
Mitsi E. et al, (2023), Nat Commun, 14
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Journal article
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Journal article
Port JR. et al, (2023), Nat Commun, 14
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Journal article
Ramasamy MN. et al, (2023), Lancet Microbe
Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.
Journal article
Maze EA. et al, (2023), Viruses, 15
The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Journal article
Dzau V. et al, (2023), Lancet
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Journal article
Neale I. et al, (2023), mBio
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
Journal article
Hornsby H. et al, (2023), Nat Commun, 14
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Journal article
Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Journal article
Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Journal article
Kaplonek P. et al, (2023), Nat Immunol